Altered radiotherapy fractionation: An opportunity not to be missed

Clinical Oncology

Volumn 10, Issue 3, 1998, Pages 150-154

  Benson, R J ^a   Burnet, N G ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCELERATION; CANCER SURVIVAL; FRACTIONATION; HEAD AND NECK CANCER; HEALTH CARE COST; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RADIOTHERAPY; SHORT SURVEY;

EID: 0031874675     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(98)80054-X     Document Type: Review

References (28)

1. Withers HR. The EORTC hyperfractionation trial [editorial; comment]. Radiother Oncol 1992;25:229-30.
2. Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomised trial. Radiother Oncol 1997;44:111-21.
3. Horiot JC, Le-Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomised trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 1992;25:229-30.
4. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a radomised multi-centrel trial. Lancet 1997;350:161-5.
5. Dische S, Saunders M, Barrett A, et al. A randomised multi-centre trial of CHART versus conventional, radiotherapy in head and neck cancer. Radiother Oncol 1997;44:123-36.
6. Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumours: overview of the randomised clinical trials. Int J Radiat Oncol Biol Phys 1997;37:259-67.
7. Suit HD. Potential for improving survival rates for the cancer patient by increasing the efficacy of treatment of the primary lesion. Cancer 1982;50:1227-34.
8. Henk JM. Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: a rationale for hypoxic cell sensitisers? Int J Radiat Oncol Biol Phys 1986;12:1339-41.
9. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997;337:949-55.
10. 125I implantation. Int J Radial Oncol Biol Phys 1991;21:537-47.
11. Improved survival with preoperative radiotherapy in resectable rectal cancer: Swedish Rectal Cancer Trial. N Engl J Med 1997;336:980-7.
12. Dunst J, Jürgens H, Sauer R, et al. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys 1995;32:919-30.
13. Withers HR, McBridge WH. Biologic basis of radiation therapy. In: Perez PA, Brady LW, editors. Principles and practice of radiation oncology, 3rd ed. Philadelphia, PA: Lippincott-Raven 1998:79-118.
14. Wilson GD, McNally NJ, Dische S, et al. Cell proliferation in human tumours measured by in vivo labelling with bromodeoxyuridine. Br J Cancer 1988;6:419-22.
15. Begg AC, Hofland I, Van Glabbeke, et al. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: results from the EORTC cooperative trial 2285. Semin Radiat Oncol 1992;1:22-5.
16. pot! Int J Radiat Oncol Biol Phys 1995;32:1539-41.
17. West CM, Davidson SE, Roberts SA, et al. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 1997;76:1184-90.
18. Dische S. Accelerated treatment and radiation myelitis [editorial]. Radiother Oncol 1991;20:1-2.
19. Coyle D, Drummond MF. Costs of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer or carcinoma of the bronchus. Clin Oncol 1997;9:313-21.
20. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31000 recurrence and 24000 deaths among 75000 women. Lancet 1992;339:1-15, 71-85.
21. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV overian cancer. N Engl J Med 1996;334:1-6.
22. Perron T. Good manners for the pharmaceutical industry. Lancet 1997;350:370-1.
23. Dale RG, Jones B. Radiobiologically based assessments of the net costs of fractionated radiotherapy. Int J Radiat Oncol Biol Phys 1996;36:739-46.
24. Withers HR, Horiot JC. Hyperfractionation. In: Withers HR, Peters L, editors. Innovations in radiation oncology. Berlin: Springer-Verlag, 1985:223.
25. Joiner MC, Lambin P, Malaise EP, et al. Hypersensitivity to very-low single radiation doses: its relationship to the adaptive response and induced radioresistance. Mutat Res 1996;355:171-83.
26. Swedish Council on Technology Assessment in Health Care (SBU). Radiotherapy for cancer. Acta Oncol 1996;35(Suppl 6):1-100;
27. Acta Oncol (Suppl 7):1-52.
28. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.